EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non–head-and-neck cutaneous squamous cell carcinoma

Wenkang Qian iD, Dongdong Jia, Hao Wu, Hanhui Zou, Haichao Xu, Tao Li iD

The Oncologist · 06.08.2026 · 31 (9)

DOI: 10.1093/oncolo/oyag252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 29.07.2026. Verfasst von Wenkang Qian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 3…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Immunotherapy, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Provincial Medical and Health Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The perioperative role of systemic therapy remains poorly defined in borderline resectable or unresectable non-head-and-neck locally advanced cutaneous squamous cell carcinoma (cSCC). We evaluated whether conversion-intent PD-1-based chemoimmunotherapy could restore surgical feasibility in this setting.

Methods

This single-center retrospective cohort study included consecutive patients with non-head-and-neck locally advanced cSCC treated with conversion-intent PD-1 inhibitor plus taxane/platinum-based chemotherapy between January 2022 and December 2025. The primary endpoint was conversion to surgical candidacy. Secondary endpoints included surgery, R0 resection, radiologic and pathologic responses, safety, and survival outcomes.

Results

Among the 28 included patients, 17 (60.7%) had unresectable disease at baseline. Following conversion-intent systemic therapy, 23 patients (82.1%) were considered eligible for surgery, and 22 (78.6%) underwent curative-intent surgery. R0 resection was achieved in 16 patients overall (57.1%) and in 72.7% of patients who underwent surgery. The objective response rate was 50.0%, the disease control rate was 89.3%, and the radiologic downstaging rate was 46.4%. Primary-site pathological complete response was observed in 18.2% of patients who underwent surgery. Treatment-related adverse events were common (85.7%), whereas grade ≥3 events were infrequent (14.3%), and permanent discontinuation and surgery delay each affected only a small minority of patients.

Conclusion

Conversion-intent PD-1-based chemoimmunotherapy was associated with restoration of surgical feasibility in selected patients with borderline resectable or unresectable non-head-and-neck locally advanced cSCC. These findings support a conversion-oriented treatment approach and suggest that surgery-related endpoints may be more informative than radiologic response alone in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorImmunotherapySkin NeoplasmsImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCutaneous Squamous Cell CarcinomaMaleRetrospective StudiesAgedMiddle AgedFeasibility StudiesAged, 80 and overPathologic Complete Response

Stichwörter der Autor:innen

PD-1 inhibitorchemoimmunotherapyconversion therapycutaneous squamous cell carcinoma

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Bone and Soft Tissue, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.

ORCID-Profile: Wenkang Qian, Tao Li

Förderung

  • Zhejiang Provincial Medical and Health Science and Technology Project

Zitieren

APA

Qian, W., Jia, D., Wu, H., Zou, H., Xu, H., & Li, T. (2026). Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non–head-and-neck cutaneous squamous cell carcinoma. The Oncologist, 31(9). https://doi.org/10.1093/oncolo/oyag252

Vancouver

Qian W, Jia D, Wu H, Zou H, Xu H, Li T. Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non–head-and-neck cutaneous squamous cell carcinoma. The Oncologist. 2026;31(9). doi:10.1093/oncolo/oyag252

BibTeX
@article{Qian2026,
  author = {Qian, Wenkang and Jia, Dongdong and Wu, Hao and Zou, Hanhui and Xu, Haichao and Li, Tao},
  title = {Conversion-intent PD-1-based chemoimmunotherapy restores surgical feasibility in borderline resectable or unresectable non–head-and-neck cutaneous squamous cell carcinoma},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {9},
  doi = {10.1093/oncolo/oyag252}
}
Kostenlos starten →